Arkolith/Insider Trading/TALS/Form 4

Agarwala Sandip

Director, 10% OwnerTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed May 11, 2021
Net Buying
Open-Market Buys
$4.0M
Open-Market Sells
$0
Net Open-Market Flow
$4.0M
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2021Conversion(C)3.0M——3.0M
May 11, 2021Buy(P)235K$17.00$4.0M3.2M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 11, 2021Conversion(C)406K—$00
May 11, 2021Conversion(C)1.3M—$00
May 11, 2021Conversion(C)1.3M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-21-019167) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML